贝利尤单抗对系统性红斑狼疮皮肤黏膜表现的疗效:五项III期临床试验的大样本事后分析
该研究整合五项III期临床试验共3086例系统性红斑狼疮(SLE)患者数据,比较贝利尤单抗与安慰剂在标准治疗基础上对皮肤黏膜BILAG(mcBILAG)和皮肤黏膜SLEDAI-2K(mcSLEDAI-2K)改善及mcBILAG发作的影响。贝利尤单抗在诱导mcBILAG与mcSLEDAI-2K改善、维持持续改善及减少抗dsDNA阳性患者mcBILAG发作方面均优于安慰剂。
要点
- 贝利尤单抗第52周诱导mcBILAG改善优于安慰剂(OR 1.29,95%CI 1.07-1.57,P=0.008)。
- 持续mcBILAG改善(HR 1.23,95%CI 1.07-1.41,P=0.003)与持续mcSLEDAI-2K改善(HR 1.24,95%CI 1.17-1.31,P<0.001)均优于安慰剂。
- 抗dsDNA阳性患者中贝利尤单抗减少mcBILAG发作(HR 0.70,95%CI 0.50-0.98,P=0.035)。
核心结论
- 贝利尤单抗在诱导SLE皮肤黏膜领域改善和预防发作方面优于安慰剂,尤其在高疾病活动度和血清学活动患者中。
研究设计与样本
- 五项III期临床试验(BLISS-52、BLISS-76、BLISS-NEA、EMBRACE、BLISS-SC)数据的大型整合事后分析,共3086例,采用logistic回归和Cox回归分析并校正试验间方差。
主要发现
- 贝利尤单抗第52周诱导mcBILAG改善优于安慰剂(OR 1.29,95%CI 1.07-1.57,P=0.008),诱导mcSLEDAI-2K改善亦优于安慰剂(OR 1.37,95%CI 1.16-1.62,P<0.001)。
- 贝利尤单抗诱导持续(≥2次访视且维持至第52周)mcBILAG改善(HR 1.23,95%CI 1.07-1.41,P=0.003)和持续mcSLEDAI-2K改善(HR 1.24,95%CI 1.17-1.31,P<0.001)均优于安慰剂。
- 上述关联在基线SLEDAI-2K≥10和抗dsDNA阳性的患者中成立,而在其对照人群中不成立。
- 抗dsDNA阳性患者中贝利尤单抗较安慰剂更多预防mcBILAG发作(HR 0.70,95%CI 0.50-0.98,P=0.035);基线SLEDAI-2K≥10患者中两组接近显著分离(HR 0.71,95%CI 0.51-1.00,P=0.050),其对照人群未见差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the efficacy of belimumab on mucocutaneous manifestations of SLE in a large integrative analysis. METHODS: Using data from five phase III clinical trials (BLISS-52; BLISS-76; BLISS-NEA; EMBRACE; BLISS-SC; N = 3086), we investigated the effect of belimumab vs. placebo on top of standard therapy on inducing improvement in mucocutaneous BILAG (mcBILAG) and mucocutaneous SLE Disease Activity Index 2000 (mcSLEDAI-2K), and on preventing mcBILAG flares. We employed logistic and Cox regression analysis, adjusting for trial variance. RESULTS: Belimumab was superior to placebo in inducing mcBILAG (week-52 OR: 1.29; 95% CI: 1.07-1.57; P = 0.008) and mcSLEDAI-2K (week-52 OR: 1.37; 95% CI: 1.16-1.62; P< 0.001) improvement, as well as in inducing sustained (≥2 visits, maintained through week 52) mcBILAG (HR: 1.23; 95% CI: 1.07-1.41; P = 0.003) and mcSLEDAI-2K (HR: 1.24; 95% CI: 1.17-1.31; P < 0.001) improvement. These associations held true for patients with SLEDAI-2K ≥10 and positive anti-dsDNA levels at baseline, but not their counter groups. Belimumab prevented mcBILAG flares to a greater extent than placebo in patients with positive anti-dsDNA levels (HR: 0.70; 95% CI: 0.50-0.98; P = 0.035) and with a near-significant separation in patients with baseline SLEDAI-2K ≥10 (HR: 0.71; 95% CI: 0.51-1.00; P = 0.050), whereas no difference was seen in their counter groups. CONCLUSION: Belimumab is superior to placebo in inducing improvement and in preventing flares in the mucocutaneous domain of SLE, especially in patients with high disease activity and in serologically active patients.
引用
- Grosso G, Giannopoulou N, Tsoi A, et al. Belimumab efficacy in mucocutaneous manifestations of systemic lupus erythematosus: a large post hoc analysis of five phase III clinical trials. Rheumatology (Oxford). 2025. PMID: 40085009. doi:10.1093/rheumatology/keaf145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。